Please Wait
Applying Filters...
menu
    • menu
    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    Lupin Manufacturing Solutions – delivering high-quality APIs & end-to-end CDMO services for faster, cost-effective drug development.

    Virtual Booth

    Contact Supplier

    Mission CDMO team brings reliability, resourcefulness, & responsiveness in executing your development project.

    Virtual Booth

    Contact Supplier

    PharmaCompass Sponsored Ads

    Virtual Booth

    Contact Supplier

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-2026-02-09

    Virtual Booth

    An Enquiry

    Menu

    1025967-78-5

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    INTERMEDIATES

    FINISHED DOSAGE FORMULATIONS

    RELATED EXCIPIENT COMPANIES

    DIGITAL CONTENT

    GLOBAL SALES INFORMATION

    MARKET PLACE

    PATENTS & EXCLUSIVITIES

    PharmaCompass
    $ API Ref.Price (USD/KG) : 19,199Xls

    Filters

    clear-filterReset all filters
    Filters Filter
    Cross PopUp
    FILTER :

    filter clear-filterReset all filters

    01 4Xiidra

    PharmaCompass
    ListList of Suppliers
    refreshReset Filter
    refresh Reset Filter
    Price Info Price Info
    product-page Product Main Page

    01

    Brand Name : Xiidra

    Lifitegrast

    arrow
    Natural Products Expo
    Not Confirmed

    Brand Name : Xiidra

    Switzerland
    arrow
    Natural Products Expo
    Not Confirmed

    Novartis

    Lifitegrast

    Main Therapeutic Indication : Ophthalmology

    Currency : USD

    2020 Revenue in Millions : 376

    2019 Revenue in Millions : 192

    Growth (%) : 96

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    02

    Brand Name : Xiidra

    Lifitegrast

    arrow
    Annual COG
    Not Confirmed

    Brand Name : Xiidra

    Switzerland
    arrow
    Annual COG
    Not Confirmed

    Novartis

    Lifitegrast

    Main Therapeutic Indication : Ophthalmology

    Currency : USD

    2021 Revenue in Millions : 468

    2020 Revenue in Millions : 376

    Growth (%) : 24

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    03

    Brand Name : Xiidra

    Lifitegrast

    arrow
    Annual COG
    Not Confirmed

    Brand Name : Xiidra

    Switzerland
    arrow
    Annual COG
    Not Confirmed

    Novartis

    Lifitegrast

    Main Therapeutic Indication : Ophthalmology

    Currency : USD

    2022 Revenue in Millions : 487

    2021 Revenue in Millions : 468

    Growth (%) : 4

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    04

    Brand Name : Xiidra

    Lifitegrast

    arrow
    Annual COG
    Not Confirmed

    Brand Name : Xiidra

    Switzerland
    arrow
    Annual COG
    Not Confirmed

    Novartis

    Lifitegrast

    Main Therapeutic Indication : Ophthalmology

    Currency : USD

    2019 Revenue in Millions : 192

    2018 Revenue in Millions : 0

    Growth (%) : N/A

    blank

    Portfolio PDF

    Product Web Link

    Virtual Booth

    Digital Content

    Website

    Corporate PDF

    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.